Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.40 |
| ▸ | PPARA | Q07869 | 9/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351025 | 0.88 | PTGDR2 (0.40) | PPARGPPARAPTGDR2MAPTPPARD | |
| SCHEMBL1990082 | 0.87 | ABCB11 (0.49) | PPARGPPARAPTGDR2MAPTPPARD | |
| SCHEMBL1989828 | 0.82 | PTGDR2 (0.40) | PPARGPPARAPTGDR2PPARDABCB11 | |
| SCHEMBL1992331 | 0.81 | ABCB11 (0.39) | PTGDR2MAPTACLYABCB11 | |
| SCHEMBL1989516 | 0.79 | PTGS2 (0.47) | ACLY | |
| SCHEMBL1992334 | 0.79 | KDM4E (0.39) | PPARGPPARAPTGDR2PPARDACLY | |
| SCHEMBL1992062 | 0.78 | ABCB11 (0.49) | PPARGPPARAPTGDR2PPARDABCB11 | |
| SCHEMBL2102466 | 0.78 | ABCB11 (0.62) | PPARGPPARAPTGDR2PPARDABCB11 | |
| SCHEMBL2347649 | 0.78 | PTGDR2 (0.40) | PTGDR2ABCB11CTSA | |
| SCHEMBL13210568 | 0.76 | PTGER1 (0.41) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PPARG 5/4885PPARA 2/4885PTGDR2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.